Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ifenprodil - Algernon Pharmaceuticals

Drug Profile

Ifenprodil - Algernon Pharmaceuticals

Alternative Names: NP 120

Latest Information Update: 07 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Algernon Pharmaceuticals
  • Developer Algernon Pharmaceuticals; Dartmouth College
  • Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antipsychotics; Antitussives; Antivirals; Benzyl compounds; Peripheral vasodilators; Phenols; Piperidines; Small molecules; Vascular disorder therapies
  • Mechanism of Action Alpha adrenergic receptor antagonists; NMDA receptor antagonists; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cough; Idiopathic pulmonary fibrosis
  • Preclinical Acute lung injury; Crohn's disease; Influenza A virus H5N1 subtype; Neuroendocrine tumours; Pancreatic cancer; Small cell lung cancer; Ulcerative colitis
  • Research Respiration disorders
  • Discontinued COVID 2019 infections

Most Recent Events

  • 01 Sep 2022 Efficacy data from a phase IIa trial in Idiopathic pulmonary fibrosis and Chronic cough released by Algernon Pharmaceuticals
  • 28 Jul 2022 Efficacy data from a phase II trial in Idiopathic pulmonary fibrosis and Cough released by Algernon Pharmaceuticals
  • 18 Jul 2022 Efficacy and adverse events data from a phase-II trial in Idiopathic pulmonary fibrosis and Cough released by Algernon Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top